Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 796-807

  Tonelli, Roberto ^a   McIntyre, Alan ^c   Camerin, Consuelo ^a   Walters, Zoë S ^c   Di Leo, Korinne ^a   Selfe, Joanna ^c   Purgato, Stefania ^a   Missiaglia, Edoardo ^c   Tortori, Andrea ^a   Renshaw, Jane ^c   Astolfi, Annalisa ^a   Taylor, Kathryn R ^c   Serravalle, Salvatore ^a   Bishop, Ryan ^c   Nanni, Cristina ^b   Valentijn, Linda J ^d   Faccini, Andrea ^e   Leuschner, Ivo ^f   Formica, Serena ^a   Reis Filho, Jorge S ^c   Ambrosini, Valentina ^b   Thway, Khin ^c,g   Franzoni, Monica ^e   Summersgill, Brenda ^c   Marchelli, Rosangela ^e   Hrelia, Patrizia ^a   Cantelli Forti, Giorgio ^a   Fanti, Stefano ^b   Corradini, Roberto ^e   Pession, Andrea ^a   Shipley, Janet ^c   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF PARMA   (Italy)

^f UNIVERSITY OF KIEL   (Germany)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PEPTIDE NUCLEIC ACID; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

7 FOXO1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FUSION GENE; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYCN GENE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; ONCOGENE; PAX3 GENE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RHABDOMYOSARCOMA; RNA INTERFERENCE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE DOSAGE; GENE THERAPY; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PEPTIDE NUCLEIC ACIDS; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856530750     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1981     Document Type: Article

References (48)

1. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010;107:163-224.
2. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80. (Pubitemid 37009955)
3. Barr FG, Duan F, Smith LM, Gustafson D, Pitts M, Hammond S, et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer 2009;48:661-72.
4. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010;10:59-64.
5. Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 2005;23:880-8. (Pubitemid 46224189)
6. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009;174:550-64.
7. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHRgene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006;66:6936-46. (Pubitemid 44197668)
8. Stegmaier S, Poremba C, Schaefer KL, Leuschner I, Kazanowska B, Bekassy AN, et al. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer 2011;57:406-14.
9. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010;28:2151-8.
10. Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Lae M, et al. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 2008; 47:510-20. (Pubitemid 351657186)
11. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008;68:9583-8.
12. Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett 2003;197:125-30. (Pubitemid 36860001)
13. Tonelli R, Purgato S, Camerin C, Fronza R, Bologna F, Alboresi S, et al. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther 2005;4:779-86. (Pubitemid 40767122)
14. Jiang R, Xue S, Jin Z. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Biochem Biophys Res Commun 2011;410:364-70.
15. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 2006;66:8139-46. (Pubitemid 44299181)
16. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010;29:1249-59.
17. Boffa LC, Cutrona G, Cilli M, Matis S, Damonte G, Mariani MR, et al. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. Cancer Gene Ther 2007;14:220-6. (Pubitemid 46106965)
18. Cutrona G, Carpaneto EM, Ulivi M, Roncella S, Landt O, Ferrarini M, et al. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol 2000;18:300-3. (Pubitemid 30159481)
19. Faccini A, Tortori A, Tedeschi T, Sforza S, Tonelli R, Pession A, et al. Circular dichroism study of DNA binding by a potential anticancer peptide nucleic acid targeted against the MYCN oncogene. Chirality 2008;20:494-500. (Pubitemid 351303990)
20. Janowski BA, Huffman KE, Schwartz JC, Ram R, Hardy D, Shames DS, et al. Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem Biol 2005;1:216-22.
21. Janowski BA, Kaihatsu K, Huffman KE, Schwartz JC, Ram R, Hardy D, et al. Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. Nat Chem Biol 2005;1:210-5.
22. Pession A, Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets 2005;5:273-83. (Pubitemid 40910560)
23. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991;254:1497-1500. (Pubitemid 21917487)
24. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006;24:816-822. (Pubitemid 46622049)
25. Summersgill B, Clark J, Shipley J. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat Protoc 2008;3:220-34. (Pubitemid 351266506)
26. Nanni C, Di Leo K, Tonelli R, Pettinato C, Rubello D, Spinelli A, et al. FDG small animal PET permits early detection of malignant cells in a xenograft murine model. Eur J Nucl Med Mol Imaging 2007;34:755-62. (Pubitemid 46669360)
27. Stanton LW, Bishop JM. Alternative processing of RNA transcribed from NMYC. Mol Cell Biol 1987;7:4266-72.
28. Armitage BA. Antigene leaps forward through an open door. Nat Chem Biol 2005;1:185-6.
29. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010;70:6497-508.
30. Ebauer M, Wachtel M, Niggli FK, Schafer BW. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 2007;26: 7267-81. (Pubitemid 350085317)
31. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66:4742-9.
32. Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK, Schafer BW. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDACinhibitors enhances combination treatment. Oncogene 2010;29:3942-52.
33. Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y, et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008;365:568-74. (Pubitemid 350181685)
34. Xia SJ, Holder DD, Pawel BR, Zhang C, Barr FG. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am J Pathol 2009;175:2600-8.
35. Sharp R, Recio JA, Jhappan C, Otsuka T, Liu S, YU Y, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002;11:1276-80. (Pubitemid 35373560)
36. Cavenee WK. Muscling in on rhabdomyosarcoma. Nat Med 2002;11: 1200-1. (Pubitemid 35373545)
37. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6: 637-45. (Pubitemid 44140861)
38. Rees H, Williamson D, Papanastasiou A, Jina N, Nabarro S, Shipley J, et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors 2006;24: 197-208. (Pubitemid 44669350)
39. Harris RG, White E, Phillips ES, Lillycrop KA. The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc. J Biol Chem 2002;38:34815-25.
40. Goljanek-Whysall K, Sweetman D, Abu-Elmagd M, Chapnik E, Dalmay T, Hornstein E, et al. MicroRNA regulation of the paired-box transcription factor Pax3 confers robustness to developmental timing of myogenesis. Proc Natl Acad Sci U S A 2011;108:11936-41.
41. Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y, Asakura A. MyoD regulates apoptosis of myoblasts through microRNA-mediated downregulation of Pax3. J Cell Biol 2010;191:347-65.
42. Rodrigues-Martins A, Riparbelli M, Callaini G, Glover DM, Bettencourt- Dias M. Revisiting the role of the mother centriole in centriole biogenesis. Science 2007;316:1046-50. (Pubitemid 46799494)
43. Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof YD, Nigg EA. Plk4-induced centriole biogenesis in human cells. Dev Cell 2007;13:190-202. (Pubitemid 47163610)
44. Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, Cho MJ, et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 2009;69:2902-11.
45. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002;1:97-104.
46. Li J, Tan M, Li L, Pamarthy D, Lawrence TS, Sun Y. SAK, A new polo- Like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia 2005;7:312-23. (Pubitemid 40664220)
47. Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 2005;24:336-46. (Pubitemid 40216138)
48. Bernasconi M, Remppis A, Fredericks WJ, Rauscher Frank J, Schafer BW. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A 1996; 23:13164-9. (Pubitemid 26382787)